共 66 条
[1]
Ndashimye E(2019)The urgent need for more potent antiretroviral therapy in low-income countries to achieve UNAIDS 90–90–90 and complete eradication of AIDS by 2030 Infect Dis Poverty. 8 63-71
[2]
Arts EJ(2020)Pretreatment HIV drug resistance and treatment failure in non-Italian HIV-1 infected patients enrolled in ARCA Antivir Ther 25 61-1858
[3]
Bavaro DF(2017)Adverse events of raltegravir and dolutegravir AIDS 31 1853-63
[4]
Di Carlo D(2017)Higher rates of neuropsychiatric adverse events leading to dolutegravir discontinuation in women and older patients HIV Med 18 56-E462
[5]
Rossetti B(2020)Dolutegravir: virologic response and tolerability of initial antiretroviral regimens for adults living with HIV PLoS ONE 15 e0238052-457
[6]
Bruzzone B(2020)High acceptability and viral suppression of patients on Dolutegravir-based first-line regimens in pilot sites in Uganda: a mixed-methods prospective cohort study PLoS ONE 15 E461-2834
[7]
Vicenti I(2020)Dolutegravir-associated hyperglycemia in patients with HIV Lancet 7 455-1203
[8]
Elzi L(2017)Discontinuation of treatment and adverse events in an Italian cohort of patients on dolutegravir AIDS 31 2831-10
[9]
Erb S(2016)Intolerance of dolutegravir-containing combination antiretroviral therapy regimens in real-life clinical practice AIDS 30 1201-201
[10]
Furrer H(2017)Neuropsychiatric adverse effects on dolutegravir: an emerging concern in Europe AIDS 13 4-446